What is Zacks Research’s Forecast for PLX Q2 Earnings?

Protalix BioTherapeutics, Inc. (NYSE:PLX) – Equities research analysts at Zacks Research issued their Q2 2026 earnings per share (EPS) estimates for Protalix BioTherapeutics in a research note issued on Thursday, May 14th. Zacks Research analyst J. Vandermosten expects that the company will earn ($0.03) per share for the quarter. The consensus estimate for Protalix BioTherapeutics’ current full-year earnings is $0.01 per share. Zacks Research also issued estimates for Protalix BioTherapeutics’ Q3 2026 earnings at ($0.03) EPS, Q4 2026 earnings at ($0.03) EPS, FY2026 earnings at $0.14 EPS and FY2027 earnings at ($0.02) EPS.

Separately, HC Wainwright reiterated a “buy” rating and issued a $12.00 price target on shares of Protalix BioTherapeutics in a report on Thursday, March 19th. One research analyst has rated the stock with a Buy rating, Based on data from MarketBeat.com, Protalix BioTherapeutics has an average rating of “Buy” and an average target price of $12.00.

Protalix BioTherapeutics Stock Performance

Shares of NYSE PLX opened at $1.91 on Tuesday. The business’s 50 day moving average price is $2.25 and its 200-day moving average price is $2.21. Protalix BioTherapeutics has a fifty-two week low of $1.32 and a fifty-two week high of $3.19. The company has a market cap of $153.89 million, a price-to-earnings ratio of -14.69 and a beta of -0.01.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. XTX Topco Ltd grew its stake in Protalix BioTherapeutics by 76.1% in the second quarter. XTX Topco Ltd now owns 73,675 shares of the company’s stock worth $109,000 after purchasing an additional 31,849 shares in the last quarter. Invesco Ltd. grew its stake in Protalix BioTherapeutics by 12.4% in the fourth quarter. Invesco Ltd. now owns 50,563 shares of the company’s stock worth $91,000 after purchasing an additional 5,560 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in Protalix BioTherapeutics in the second quarter worth approximately $56,000. JPMorgan Chase & Co. grew its stake in Protalix BioTherapeutics by 2,065.8% in the second quarter. JPMorgan Chase & Co. now owns 34,545 shares of the company’s stock worth $51,000 after purchasing an additional 32,950 shares in the last quarter. Finally, Marshall Wace LLP bought a new position in Protalix BioTherapeutics in the fourth quarter worth approximately $34,000. Institutional investors own 16.53% of the company’s stock.

About Protalix BioTherapeutics

Protalix BioTherapeutics (NYSE:PLX) is a clinical‐stage biopharmaceutical company focused on the development and manufacturing of recombinant therapeutic proteins through its proprietary ProCellEx® plant cell–based expression system. Headquartered in Carmiel, Israel, with operations in the United States, the company leverages its technology platform to produce complex biologics in a cost‐effective and scalable manner. Protalix’s core expertise lies in engineering plant cells to generate high‐quality therapeutic proteins for rare and specialty diseases.

The company’s first approved commercial product, ELELYSO® (taliglucerase alfa), received regulatory approval from the U.S.